This site contains information about prescription peptide therapy protocols intended for adults. You must be 18 years of age or older to enter.
By entering, you confirm you are at least 18 years old and agree to our Terms of Service. All protocols require a valid physician prescription.
An 83-amino acid analogue of Insulin-Like Growth Factor-1 — engineered with an arginine substitution at position 3 and a 13-amino acid N-terminal extension that prevents binding to IGF Binding Proteins (IGFBPs). The result: a ~20–30 hour circulating half-life versus the ~10 minute half-life of native IGF-1, with full IGF-1 receptor potency.
Native IGF-1 has a half-life of approximately 10 minutes in circulation — immediately bound by a family of IGF Binding Proteins (IGFBP-1 through IGFBP-6) that regulate its availability and delivery. While the body uses this binding to modulate IGF-1 action precisely, it also means that injected native IGF-1 is cleared so rapidly that sustained receptor activation is difficult to achieve.
IGF-1 LR3 solves this by substituting arginine at position 3 (which reduces IGFBP-3 affinity dramatically) and adding a 13-amino acid extension at the N-terminus. The result is a molecule that maintains full affinity for the IGF-1 receptor but circulates freely — extending biological half-life to approximately 20–30 hours. A single injection activates IGF-1R across muscle, fat, liver, and other tissues for a sustained period.
IGF-1 signaling drives cell proliferation and inhibits apoptosis through PI3K/Akt/mTOR and Raf/MEK/ERK pathways. This is the mechanism behind its anabolic effects on muscle — but the same pathways are known drivers of cancer cell growth. Epidemiological data from the Biomolecules review (2021) found that individuals in the top 20% of endogenous IGF-1 concentration had a 1.24-fold increased breast cancer risk, a 21% higher prostate cancer risk per standard deviation increase, and a 1.82-fold increase in cancer mortality at levels above 100 ng/mL baseline. These are population-level associations at elevated endogenous levels — not controlled trial data — but the signal is consistent across multiple studies. IGF-1 LR3 research is not appropriate for individuals with a personal or family history of hormone-sensitive or proliferative cancers. This is a meaningful safety consideration, not a footnote.
IGF-1R activation → PI3K/Akt/mTOR cascade → increased ribosomal protein synthesis and nitrogen retention. The downstream anabolic signaling is equivalent to the GH → IGF-1 axis that regulates muscle mass in normal physiology.
IGF-1 is a primary activator of muscle satellite cells — the resident stem cells responsible for muscle fiber repair and growth. LR3's extended half-life produces sustained satellite cell recruitment, studied for muscle wasting and regeneration models.
IGF-1 analogues are studied in models of cachexia, sarcopenia, ALS, and other muscle wasting conditions where the GH-IGF-1 axis is impaired. LR3's pharmacokinetic profile makes it practical for sustained research protocols.
IGF-1R activation in adipose tissue promotes lipolysis. IGF-1 LR3 studies show reduction in adipose tissue alongside lean mass improvements — the classic anabolic/lipolytic profile associated with GH/IGF-1 axis activity.
IGF-1 promotes repair in cartilage, tendon, and bone through chondrocyte and osteoblast activation. LR3's extended duration of action is studied in orthopedic injury and recovery research models.
IGF-1 receptors are expressed throughout the CNS. IGF-1 signaling supports neuronal survival, synaptic plasticity, and myelination — areas of study in neurodegenerative disease models and CNS recovery research.
Arg3 substitution + 13-AA N-terminal extension reduces IGFBP binding. Half-life: 20–30 hours. Remains in systemic circulation for sustained receptor activation. Single daily injection achieves meaningful circulating concentrations. Approximately 3× more potent at the receptor than native IGF-1 due to reduced binding protein interference.
Immediately sequestered by IGFBPs (especially IGFBP-3). Half-life: ~10 minutes free, hours-days when IGFBP-bound. Highly regulated by the liver and binding protein system. Injected native IGF-1 may not achieve meaningful free receptor activation before being bound. LR3 was specifically engineered to circumvent this limitation.
IGF-1 LR3 dosing in research is typically post-workout for muscle-focused protocols, or daily at a set time for systemic research applications. Cycling is strongly recommended given the cell growth implications of sustained IGF-1R activation.
| Protocol | Dose | Frequency | Notes |
|---|---|---|---|
| Standard | 20–50mcg SC or IM | Daily or post-workout | Post-workout IM injection to worked muscle groups is a common research approach — local IGF-1R activation in the exercised tissue. SC for systemic application. |
| Higher range | 50–100mcg SC | Daily | Upper research range. Risk of hypoglycemia increases at higher doses — IGF-1 has insulin-like activity. Assess response carefully at each dose increment. |
| Cycle | — | 4–6 weeks on, 4 weeks off | Cycling is important. Receptor desensitization occurs with continuous use; sustained IGF-1R stimulation also has cell growth implications that warrant periodic breaks. |
The LR3 modification extends circulating half-life from ~10 minutes (native IGF-1) to 20–30 hours — the engineering decision that makes sustained IGF-1R research practical.
IGF-1R → IRS-1 → PI3K → Akt → mTOR is the canonical anabolic signaling cascade activated by IGF-1 LR3. mTOR complex 1 (mTORC1) coordinates ribosomal assembly and protein synthesis.
Due to reduced IGFBP sequestration, IGF-1 LR3 produces approximately 3× more free receptor activation than equivalent native IGF-1. Context: IGFBP-3 alone accounts for ~80% of all bound circulating IGF-1, and roughly 98% of native IGF-1 is protein-bound at any given time. LR3's reduced affinity for IGFBPs circumvents this regulatory system.
IGF-1 and its analogues (including LR3) are prohibited by WADA in competitive sport. Notably, there is still no internationally recognized test for detecting exogenous IGF-1 use in athletes — making it one of few prohibited substances that cannot be reliably detected at present. For non-athlete patients, the WADA classification reflects regulatory acknowledgment of the compound's physiological effects.
IGF-1 LR3 is typically used as a standalone anabolic research peptide. It can be combined with tissue repair peptides that work through different pathways:
Do not combine with other IGF-1 pathway activators (native IGF-1, IGF-DES) without research justification — overlapping receptor saturation without additive benefit.
Third-party COA, Finnrick-verified purity. Available in 0.1mg and 1mg vials. Ships within 24 hours.
Start Protocol Intake ← All ProtocolsMedical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. All protocols require evaluation and prescription by a licensed physician. You should consult a qualified healthcare provider before starting any new medical protocol. Individual results vary. Cinch Bio is not a pharmacy and does not dispense medications — all prescriptions are issued by independent licensed physicians and filled by licensed 503A compounding pharmacies.